EIDD-1723

EIDD-1723 is a Progesterone (HY-N0437) analogues, that binds progesterone receptor (PR) with an IC50 of 2.25 μM. EIDD-1723 is the prodrug of EIDD-036 (HY-17649) . EIDD-1723 may exert its neuroprotective effects not solely through progesterone receptor (PR) -dependent pathways but also via non-genomic mechanisms, such as modulation of inflammatory responses and oxidative stress. EIDD-1723 can be used for the study of traumatic brain injury (TBI) [1][2][3].

Product Specifications

CAS Number

[1659302-89-2]

UNSPSC

12352211

Target

Progesterone Receptor

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Endocrinology; Neurological Disease

Smiles

C[C@@]12[C@](CC[C@@H]2/C(C)=N/OCOP(O[Na])(O[Na])=O)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4(C(CC3)=CC(CC4)=O)C

Molecular Formula

C22H32NNa2O6P

Molecular Weight

483.45

References & Citations

[1]Wali B, et al. Evaluating the neurotherapeutic potential of a water-soluble progesterone analog after traumatic brain injury in rats. Neuropharmacology. 2016 Oct;109:148-158.|[2]Fritzemeier RG, et al. Neurotherapeutic Potential of Water-Soluble pH-Responsive Prodrugs of EIDD-036 in Traumatic Brain Injury. J Med Chem. 2023 Apr 27;66 (8) :5397-5414.|[3]Sayeed I, et al. Development of a novel progesterone analog in the treatment of traumatic brain injury. Neuropharmacology. 2019 Feb;145 (Pt B) :292-298.